Sylvester, R. J. Bacillus Calmette-Guerin versus mitomycin C for the treatment of intermediate-risk non-muscle-invasive bladder cancer: the debate continues. Eur. Urol. 56 , 266–268 (2009).

Existing phase 2 data on CG0070 in Bacillus Calmette–Guérin-unresponsive patients with nonmuscle invasive bladder cancer show a robust complete response rate, with durable responses seen in a ...

The bacillus Calmette–Guérin (BCG) vaccine, initially developed to provide protection against TB, also protects against leprosy; and the magnitude of this effect varies. Previous meta-analyses ...

BCG (Bacillus Calmette-Guerin) vaccine for tuberculosis, pictured at the Pasteur Institute in Paris in 1931. Scientists in the UK have begun testing the BCG vaccine, developed in 1921, to see if ...

for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary ...

As a first-time parent, protecting your baby’s health is your top priority—and vaccinations are one of the most effective ...

The only vaccine against TB, the Bacillus Calmette-Guérin vaccine, has been used for more than 100 years. It is largely effective for children under five, but less so in older people. And it can ...

Bacillus of Calmette and Guerin (BCG) strain of Mycobacterium bovis live, attenuated culture preparation; 50mg per vial; pwd for intravesical administration after reconstitution and dilution ...

BOSTON & MONTREAL, November 25, 2024--enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage ...